Gerald Falchook, MD
Medical Oncology · Denver, CONPI 1366541294
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Amgen at 34.5% of the total. Reporting peaked in 2022 at $8,001 and has fallen 95.7% since, to $346 in 2025.
Across 53 payments — averaging $380.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- Boehringer Ingelheim International GmbH$4K
- AbbVie$3K
- Regeneron Healthcare Solutions, Inc.$3K
- Merck$2K
- Beigene USA, Inc.$141
- plus $944 from 22 others
Across 2,370 payments — averaging $6793.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$4.6M
- GSK$2M
- Merck$1.4M
- Tesaro, Inc.$1.4M
- Takeda Pharmaceuticals U.S.A., Inc.$955K
- Regeneron$923K
- plus $4.7M from 21 others
What the payments were for
- Consulting fees$7,62438%
- Speaking & faculty fees$4,33722%
- Travel & lodging$6,93134%
- Food & beverage$1,2116%
- Gifts$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $6,956 |
| Boehringer Ingelheim International GmbH | 5 | $4,337 |
| AbbVie | 2 | $2,899 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,620 |
| Merck | 5 | $2,261 |
| Beigene USA, Inc. | 1 | $141 |
| AstraZeneca | 2 | $130 |
| Pfizer | 6 | $111 |
| Boehringer Ingelheim | 1 | $78 |
| EMD Serono, Inc. | 3 | $64 |
| Tempus AI, Inc | 3 | $62 |
| Deciphera Pharmaceuticals Inc. | 1 | $55 |
| Incyte Corporation | 2 | $51 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Array Biopharma Inc | 2 | $38 |
| Delcath Systems | 1 | $36 |
| Astellas Pharma US Inc | 1 | $34 |
| Genmab U.S., Inc. | 1 | $34 |
| Spectrum Pharmaceuticals Inc. | 1 | $28 |
| Caris MPI, Inc. | 1 | $27 |
| Tersera Therapeutics LLC | 1 | $26 |
| Coherus Oncology, Inc. | 1 | $21 |
| Foundation Medicine, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Seagen Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,158 in reported general payments places this provider in the 80th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Denver
- Laurie CarrDenver$46K
- Jose MayordomoDenver$1K
- Heather WestDenver$857
- Scott KonoDenver$439
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Chelsea GawryletzFort Collins$301K
- Sapna PatelAurora$186K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.